Researchers identify vulnerabilities of the deadly Ebola virus

Disabling a protein in Ebola virus cells can stop the virus from replicating and infecting the host, according to researchers from the Icahn School of Medicine at Mount Sinai. The data are published in July in the journal Cell Host and Microbe.

Ebola viruses cause severe disease in humans because they can deactivate the . Christopher Basler, PhD, Associate Professor of Microbiology at Mount Sinai and his team have studied how Ebola viruses evade the immune system, and discovered that a called VP35 is critical to deactivating the immune system. They found that when VP35 interacts with an important called PACT, it blocks PACT from activating the immune system, allowing the virus to spread.

"Ebola viruses are extremely lethal, and are a great threat to human health as a bioweapon," said Dr. Basler. "Currently, there is no approved vaccine or treatment. Our findings will hopefully pave the way for future antiviral treatments."

With the help of collaborators at the University of Texas with access to special high containment facilities, Dr. Basler and his team infected healthy cells with Ebola virus cells that had mutated versions of VP35. The mutations disabled VP35's ability to interact with PACT, therefore allowing it to activate the immune system and prevent the virus from replicating. Next, the researchers overexpressed PACT in healthy cells, and infected them with Ebola virus cells. They found that overexpressing PACT also inhibited .

Armed with this discovery, Dr. Basler and his team hope to develop drugs that disrupt the interaction of VP35 with PACT, or drugs that overexpress PACT.

Related Stories

Researchers discover Ebola's deadly secret

Jan 19, 2010

(PhysOrg.com) -- Research at Iowa State University has led scientists to uncover how the deadly Zaire Ebola virus decoys cells and eventually kills them.

Ebola's secret weapon revealed

May 02, 2013

Researchers have discovered the mechanism behind one of the Ebola virus' most dangerous attributes: its ability to disarm the adaptive immune system.

Recommended for you

Organovo has 3D-printed liver tissue for drug testing

Nov 20, 2014

(Medical Xpress)—The commercial release of 3D printed liver tissue was announced earlier this week. Organovo is the company behind the release. The product is intended for use for preclinical drug discovery ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.